Zifa TR150 mg+0.5 mg+61.8 mg

Zifa TR is a combined hematinic and mineral supplement in which ferrous sulfate supplies elemental iron for hemoglobin synthesis, folic acid supports red blood cell DNA synthesis and maturation, and zinc sulfate monohydrate supports immune function and growth. It is used for the following indications, classified by strength of evidence:

Established / Guideline-Supported Uses

• Treatment and prevention of nutritional anemia due to combined iron and/or folate deficiency, including iron-deficiency anemia and megaloblastic anemia of nutritional origin, when a combined hematinic is appropriate.
• Prevention and treatment of iron, folic acid, and zinc deficiency during pregnancy and lactation, when increased physiological requirements are not met by diet alone, as directed by a physician (see Pregnancy and Lactation).
• General hematinic and mineral supplementation in individuals with proven or likely dietary insufficiency of iron, folate, and zinc (e.g. poor dietary intake, malabsorption states, or increased requirement).

Zifa TR is a supplement intended to correct or prevent specific nutritional deficiencies; it does not treat anemia due to other causes (e.g. vitamin B12 deficiency, chronic disease, hemoglobinopathy) and is not a substitute for investigating the underlying cause of anemia. Use should be guided by a physician, ideally with confirmation of deficiency where practical.

Ferrous Sulfate + Folic Acid + Zinc Sulfate Monohydrate is typically formulated as a capsule or tablet containing Ferrous Sulfate BP (commonly around 150 mg, equivalent to approximately 47 mg elemental iron), Folic Acid BP (commonly around 500 mcg), and Zinc Sulfate Monohydrate USP (commonly around 61.8 mg, equivalent to approximately 22.5 mg elemental zinc) per unit dose. Exact strengths vary by brand and formulation (including timed-release/sustained-release preparations); refer to the specific product label for the precise elemental iron, folic acid, and elemental zinc content.

Zifa TR is an oral combination supplement of ferrous sulfate (an iron salt), folic acid (a B-group vitamin), and zinc sulfate monohydrate (a zinc salt). It is available as tablets or capsules, including timed-release formulations designed to release iron gradually and reduce gastrointestinal irritation.

Iron is an essential mineral required for hemoglobin synthesis and oxygen transport; folic acid is required for DNA synthesis and normal red blood cell maturation; zinc is an essential trace mineral involved in immune function, wound healing, growth, and numerous enzymatic processes. Zifa TR is widely used to prevent and correct combined deficiencies of these three nutrients, particularly in pregnancy, lactation, and states of poor dietary intake.

Zifa TR belongs to the therapeutic class of Iron, Vitamin and Mineral combined preparations (Hematinics), used as a nutritional supplement for the prevention and treatment of iron, folate, and zinc deficiency.

Ferrous Sulfate + Folic Acid + Zinc Sulfate Monohydrate combines three agents with complementary mechanisms:

• Ferrous sulfate provides ferrous (Fe2+) iron, which is absorbed mainly in the duodenum and proximal jejunum, transported in plasma bound to transferrin, and incorporated into hemoglobin in developing red blood cells, and into myoglobin and various iron-dependent enzymes. Correcting iron deficiency restores hemoglobin synthesis and resolves iron-deficiency anemia.
• Folic acid is converted to its active metabolite, tetrahydrofolate, which acts as a coenzyme in one-carbon transfer reactions required for purine and pyrimidine (DNA) synthesis. Adequate folate is essential for normal erythropoiesis and rapid cell division, and its deficiency causes megaloblastic anemia.
• Zinc sulfate monohydrate supplies elemental zinc, a cofactor for numerous metalloenzymes involved in protein and nucleic acid synthesis, immune cell function, wound healing, and normal growth and development; zinc deficiency impairs immunity, growth, and taste/appetite.

Together, the components of Ferrous Sulfate + Folic Acid + Zinc Sulfate Monohydrate address overlapping and commonly co-occurring nutritional deficiencies, supporting normal hematopoiesis, immune function, and growth.

Zifa TR should be taken orally, ideally on an empty stomach for best absorption, or with a small amount of food if gastric irritation occurs. Doses should be spaced apart from tea, coffee, dairy products, antacids, and certain other medicines that reduce iron or zinc absorption (see Interaction). Timed-release capsules/tablets should be swallowed whole; if a capsule formulation permits, it may be opened and its contents mixed with soft food (not chewed) for patients who cannot swallow it whole.

Zifa TR has the following well-established, clinically significant interactions:

• Tetracycline and fluoroquinolone antibiotics (e.g. tetracycline, doxycycline, ciprofloxacin): both iron and zinc chelate with these antibiotics in the gut, substantially reducing absorption of both the antibiotic and the mineral. Separate dosing by at least 2–3 hours.
• Penicillamine: iron and zinc can reduce penicillamine absorption and penicillamine can reduce iron/zinc absorption; separate dosing by several hours if concurrent use is necessary.
• Antacids and proton pump inhibitors/H2-blockers: reduce gastric acidity needed for iron absorption, and antacids containing calcium or magnesium can also chelate iron and zinc, reducing absorption of Zifa TR; separate dosing by at least 2 hours where possible.
• Levothyroxine: iron can reduce absorption of levothyroxine if taken together; separate administration by at least 4 hours.
• Calcium and dairy products: calcium and phytates in dairy/food can reduce iron and zinc absorption; avoid taking Zifa TR with milk or calcium supplements.
• Penicillamine, copper, and long-term high-dose use: prolonged zinc supplementation without adequate copper intake can cause copper deficiency; monitor with prolonged use.
• Other iron-fortified or mineral-fortified products: concurrent use of other iron- or zinc-containing supplements, multivitamins, or fortified foods increases the risk of iron/zinc excess; avoid duplicate supplementation unless directed by a physician.

Zifa TR is generally well tolerated at recommended doses, though gastrointestinal effects related to the iron component are common. Reported adverse effects include:

• Very common: dark or black-colored stools (a harmless, expected effect of the iron component).
• Common: nausea, constipation, diarrhea, abdominal discomfort, and loss of appetite.
• Less common: vomiting, metallic taste (associated with the zinc component), and heartburn.
• Rare: allergic/hypersensitivity reactions (e.g. rash, itching). Prolonged high-dose zinc use can rarely cause copper deficiency with associated anemia or neurological symptoms (see Precautions and Warnings).

Zifa TR is commonly recommended and considered beneficial during pregnancy and lactation to prevent and treat pregnancy-associated iron, folate, and zinc deficiency, and folic acid supplementation supports fetal neural tube development. However, routine iron supplementation in the first trimester should generally be avoided unless deficiency has been proven and the potential benefit justifies the potential risk, since iron requirements are lower and gastrointestinal tolerance may be reduced in early pregnancy; folic acid and zinc supplementation are generally considered appropriate throughout pregnancy as directed by a physician. Zifa TR should be used only as directed by a physician, with the dose individualized to trimester and confirmed or likely deficiency. Iron, folic acid, and zinc are also compatible with breastfeeding at recommended supplemental doses, but a physician should be consulted before use during lactation.

The following precautions apply to use of Zifa TR:

• Keep out of reach of children. Iron-containing products, including Zifa TR, are a serious cause of accidental pediatric poisoning; accidental overdose of iron in a child is a medical emergency (see Overdose).
• Use with caution and under medical supervision in patients at risk of iron overload, including those with a family history of hemochromatosis, hemolytic anemia, or red cell aplasia, and in those receiving repeated blood transfusions.
• Folic acid supplementation can mask the hematologic (blood count) signs of vitamin B12 deficiency while allowing underlying neurological damage from B12 deficiency to progress; proper evaluation for B12 deficiency is advisable before or during use if megaloblastic anemia is suspected, particularly in elderly patients or those at risk of B12 deficiency.
• Prolonged, high-dose zinc supplementation without adequate dietary copper can cause copper deficiency, which may present as anemia or neurological symptoms; avoid unsupervised long-term high-dose use.
• Use with caution in renal impairment/renal failure due to increased risk of zinc accumulation.
• Avoid concurrent use with other iron-fortified, folic-acid-fortified, or zinc-fortified products unless directed by a physician, to avoid excess intake.
• Zifa TR is not an antibiotic and carries no antimicrobial stewardship requirement, but should still be taken exactly as directed and not shared with others without medical advice, since individual dosing needs vary.

Overdose of Zifa TR, particularly the iron component, is potentially serious and can be fatal, especially in young children who may ingest tablets/capsules accidentally. Symptoms of acute iron overdose can include nausea, vomiting (sometimes with blood), abdominal pain, diarrhea, lethargy, and, in severe cases, shock, metabolic acidosis, liver damage, and cardiovascular collapse, sometimes after a deceptive period of apparent improvement. Excessive zinc intake can cause nausea, vomiting, and, with chronic excess, copper deficiency. If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away, even if the person appears well; do not attempt specific home treatment or induce vomiting without medical advice. Management requires prompt medical evaluation and is directed by a healthcare professional.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Pediatric Use

Zifa TR may be used in children older than one year for treatment and prevention of combined iron, folic acid, and zinc deficiency, using age-appropriate dosing; capsule contents may be mixed with soft food (not chewed) if the child cannot swallow the capsule whole. Use in infants under one year should be individualized by a pediatrician. See Pediatric Uses.

Elderly

Zifa TR is commonly used in elderly patients with nutritional anemia or dietary insufficiency; folic acid supplementation in this group can mask underlying vitamin B12 deficiency, which is more common with advancing age, so evaluation for B12 deficiency is advisable if anemia is present (see Precautions and Warnings).

Renal Impairment

Use with caution and under medical supervision, as renal impairment increases the risk of zinc accumulation; dose adjustment or closer monitoring may be needed.

Hepatic Impairment

No well-established dose adjustment is required for hepatic impairment, but patients with significant liver disease may have altered iron handling; use under medical supervision.

Duration of Zifa TR therapy depends on the indication: treatment of confirmed iron/folate/zinc deficiency anemia is typically continued for several months (often 3–6 months) after hemoglobin normalizes to replenish body iron stores, while use during pregnancy and lactation is usually continued for the relevant duration as directed by a physician, with periodic reassessment of blood counts and iron/zinc status.

Hematinic (iron salt); folate supplement; trace mineral (zinc) supplement; combined iron-vitamin-mineral preparation.

Ferrous Sulfate + Folic Acid + Zinc Sulfate Monohydrate acts by supplying elemental iron (from ferrous sulfate) for incorporation into hemoglobin and correction of iron-deficiency anemia, folic acid (converted to tetrahydrofolate) to support DNA synthesis and normal red blood cell maturation, and elemental zinc (from zinc sulfate monohydrate) as a cofactor for enzymes involved in immune function, growth, and tissue repair, together correcting combined nutritional deficiencies of these three micronutrients.

Zifa TR is used in children older than one year for the treatment and prevention of combined iron, folic acid, and zinc deficiency and associated nutritional anemia, at a dose of one capsule/tablet daily unless otherwise directed by a pediatrician; the capsule may be opened and its pellets mixed with soft food (not chewed) for children who cannot swallow it whole. Use in infants under one year of age should be individualized by a pediatrician, as safety and dosing in this age group are less well established. Because accidental ingestion of iron-containing products is a leading cause of pediatric poisoning, Zifa TR must be kept out of reach of children at all times.